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671). The mean annual overall direct health care cost for using lactate-based bal-
anced solution was estimated to be 2.16 billion rubles ($40.3 million), and for using 
acetate-based balanced solution - 2.05 billion rubles ($38.3 million). The CMA has 
shown that annual savings when used as a balanced infusion therapy acetate-based 
solution will be 110 million rubles ($ 2.05 million). ConClusions: The using for 
infusion therapy acetate-based balanced solution Jonosteril® was more economi-
cally justified treatment option.
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objeCtives: Despite concerns about interchangeability and substitution of bio-
similar products with reference products, they provide cost savings either by 
leading price reductions or increase in discounts of reference products. There 
are several studies demonstrating the actual/potential cost saving effects of bio-
similars. In this regard, the aim of this study is to define the price reductions 
or increase in discounts of reference products by the reimbursement of their 
biosimilars in Turkey. Methods: Biotechnology products, which are still avail-
able in the market, are selected from the list of pharmaceutical products pub-
lished on the Ministry of Health’s web site. Their registration dates and ex-factory 
prices and statuary discounts between 2009 and 2014 are searched. Afterwards, 
the change in the reference products’ ex-factory prices and statuary discounts 
is analyzed for the first year that biosimilar products are reimbursed. Results: 
Not considering the different forms of drugs there are 80 biotechnology products 
(66 active ingredients) being marketed in Turkish pharmaceutical market. 10 of 
them are biosimilar products (7 active ingredient). The first biotechnology product 
and the biosimilar product were registered in Turkey in 1992 and 2009 respec-
tively. Only 4 active ingredients have both biosimilar and the reference product. 
By the reimbursement of the biosimilar products, the statuary discount of all 
the reference products increased between %14 and %113 and the price of the 2 
reference product decreased by %26 and %31 while the prices of other products 
didn’t change. ConClusions: Depending on the analysis bio-similars may have 
a cost-reduction impact on pharmaceutical budgets. Further analysis should be 
conducted on the reason of price reductions of reference products by penetration 
of biosimilars whether by leading direct reductions or increased discounts in order 
to exempt the effect or general pricing regulations or cost containment measures 
unlikely to be specific to biotechnology products.
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objeCtives: To understand how EU healthcare decision makers define value when 
assessing biosimilar treatments Methods: Combination of desk research to track 
current biosimilar market trends, followed by qualitative research including one-to-
one interviews with six EU sub-national payers and key opinion leaders. Results: 
European payers consider more than just list and net prices when purchasing and 
supplying novel biosimilar treatments for patients. Whilst payers do consider key 
aspects such as product attributes in the decision making process, it is economic 
and public health benefits, supply chain quality, reputation of the manufacturer, 
national guidance, support and demand from key units or physicians within their 
region, that remain as the most influential factors in the decision making pro-
cess. ConClusions: Many EU payers still consider value beyond just price of a new 
medicine. However, recent biosimilar launches in the Nordics are challenging this 
paradigm and affecting discount expectations on biosimilars vs. original compounds 
in western EU countries. While sub-national payers need to ensure that biosimilar 
medicines can be supplied to their patients at a consistent level of quality and quan-
tity, biosimilar manufacturers need to ensure new compounds are launched into 
the market, at suitable price, with a successful commercial strategy that includes 
dedicated sales and marketing efforts. Moving forward, it will be important for bio-
similar manufacturers to understand what payers, physicians and patients value 
within a new medicine before entering price discussions.
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objeCtives: In Brazil, law regulates the use of human albumin and divide recom-
mendations into formal, questionable and unsubstantiated. The aim was to verify 
compliance with the requirements of this medicine in relation to national guidelines 
and calculate the costs of unsubstantiated indications of human albumin 20%, 
at a public hospital. Methods: We evaluated the records of patients who used 
human albumin 20% during hospitalization at a public hospital in the period from 
August, 2013 to August, 2014. There were no restrictions as patient age or duration of 
therapy. Quantitative variables were expressed as by mean and standard deviation, 
and not quantitative variables in by absolute and relative frequency. Results: We 
evaluated the records of 63 patients with a mean age of 60.6 ± 71.8 years. Most of 
them were men (40; 64.5%). Length of stay was 30.0 ± 47.2 days. Duration of albu-
min therapy was 6.0 ± 6.7 days (mean). Average total cost was US $ 174.13 ± 195.10 
per patient. Nineteen (30.2%) of albumin indication was classified as questionable 
and 15 (23.8%) as unsubstantiated. Cost of unsubstantiated indications was US $ 
2,379.80/year or US $ 158.65/patient, this represents 21.7% costs of albumin during 
the study period. Unsubstantiated indications were: use in intensive care (12; 19.0%), 
fluid replacement in acute losses (2; 3.2%) and hypoalbuminemia in patients with 
Suppliers were also observed to charge different prices for the same brands to 
different public hospitals, indicating information asymmetry on reasonable prices 
of drugs. ConClusions: Based on the observed wide variations in drug procure-
ment prices in the Philippines, setting the DPRI at the median value for most 
drugs was found to be an appropriate method to set ceiling prices for public sector 
procurement. For monopolized pharmaceutical products, other methods may be 
more appropriate such as value-based pricing, price negotiations and external 
reference pricing to relevant countries.
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objeCtives: To work out the cost-benefit analysis (CBA) of the infrastructural devel-
opment major project of Jósa András Teaching Hospital (Nyíregyháza, Hungary) 
funded by EU grants. Two supported projects (complex hospital development and 
an integratedemergency care unit) were merged and had to be revised according 
to the major project requirements because of the recent significant cost increases. 
At the end of 2014 the project in value of 56.15 million EUR was submitted to the 
European Commission. Methods: The CBA was based on the guidelines outlined 
in the EU Regional Policy and concerning Working Document. A 25-year time horizon 
was determined . 5% financial and 5.5% social discount rate were applied, as recom-
mended in the guidelines. Analyses were conducted using the incremental method 
considering Business as usual and Project scenario. To express the monetary value 
of socio-economic benefits we applied the willingness-to-pay method. The value of 
24,772 EUR was used as an average value of human life year based on the published 
data (EuroVaq) regarding the Hungarian population. Aggregating socio-economic 
benefits, we considered the monetized values of the following health gains: reduc-
tion in the 30-day AMI death rate, in county cancer deaths, in infant mortality, in 
the number of registered people with permanent disabilities, in lost income and 
health gain attainable through improving the quality of care. Results: Financial 
net present value (-50.6 million EUR), economic net present value (27.3 million EUR), 
financial rate of return (-8.15%), economic rate of return (9.44%) and cost-benefit 
ratio (1.62) were calculated as results of CBA. ConClusions: The CBA reflected the 
fact that health care investments in the public sector are not directly financially 
recovered for the owner, but - considering the broader socio-economic effects - the 
project meets the requirement that the level of socio-economic benefits are higher 
than the socio-economic costs.
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objeCtives: The shorter the response time of emergency services the more lives are 
saved. But, how important in fact is the time factor for saving lives? The objective of 
this study is to analyse the relation between response time and fatalities, to be able 
to measure how many lives could be saved with a shorter response time. Methods: 
The study uses data from reports from the fire and rescue services in Sweden for 
2005–2013 for residential fires. The time variable used is continuous and the sta-
tistical methods are non-linear regression techniques. Results: It is found that 
the risk of fatality is a non-linear function of response time. The marginal effect 
of response time is first large, then decreases, and eventually seems to approach 
zero. If it was possible to decrease the median response time by one minute 0.00035 
lives could be saved for every turn-out. For all turn-outs to residential homes that 
means that about two lives, or 3%, could be saved per year. The response time 
is most important for blocks of flats, nursing homes and semi-detached/terraced 
houses. The response time is more important for fires due to smoking, children 
playing or started intentionally (arson). ConClusions: The results can be used to 
evaluate the performance of local fire and rescue services. It can also be used as a 
planning tool for fire and rescue services when it comes to the importance of dif-
ferent causes of injuries. The method is easy to use for other emergency services, 
such as ambulances.
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objeCtives: The main aim of this study was to conduct a comparative phar-
macoeconomic analysis of the using 2 variants of balanced crystalloids infusion 
therapy – acetate- (Jonosteril®) and lactate-based (Sterofundin ISO®). Methods: 
Analysis of the published clinical trials was conducted to evaluate comparative 
efficacy and safety of using balanced solutions of different composition. Direct 
medical costs for using 2 variants of balanced infusion therapy were calculated. 
Taking into account the hypothesis of equal effectiveness of balanced solutions of 
different compositions for pharmacoeconomic analysis was chosen “cost minimi-
zation” analysis (CMA). To calculate the direct costs of infusion therapy was deter-
mined the average duration of infusion therapy in patients with traumatic shock 
conditions in the intensive care unit on the basis of the actual practice of the N.V. 
Sklifosovsky Research Institute of Emergency Care. Direct costs were included the 
cost of one day of application infusion therapy on the basis of 2000 ml per day for 1 
patient. Results: According to published trials the using of different combinations 
of crystalloids such as acetate- and lactate-based were provided equal hemody-
namic stability. The average cost of a course of infusion therapy in patients with 
traumatic shock conditions by using acetate-balanced based solution was 34 104 
rubles ($ 636.8), and by using lactate- based balanced solution - 35 936.8 rubles ($ 
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the changes in business condition in Japan’s healthcare system. Methods: The 
financial statements of all 143 NHO hospitals from 2004 to 2013 were obtained to 
explore the changes in their financial conditions. We analysed them with total 
health expenditures and the revision rates of the medical fee schedule available 
from the government websites. Results: The medical fee schedule was reduced 
by 3.16% in 2006 and 0.82% in 2008, and then increased by 0.19% in 2010 and 0.004% 
in 2012. The change rate of the profit per bed in NHO hospitals was overall parallel 
to the change rate of total health expenditure except for 2010 when the change 
rates were increased in 6.9% and 3.9% respectively. The reason of the exception 
in 2010 can be associated with the transition to acute care in line with the gov-
ernment policy to promote functional differentiation of hospitals. NHO hospitals 
with more than 350 beds had continuously increased the change rate of profit 
per bed despite of the negative revisions to the medical fee schedule in 2006 and 
2008. ConClusions: Clear influence of the manipulation of the medical fee sched-
ule was observed over the profit per bed in NHO hospitals. The rate of increase in 
total health expenditure was fairly controlled by the government through the revi-
sion of the medical fee schedule.
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objeCtives: The aim of our study was to predict the future health insur-
ance expenditures according to the changes in the number of population in 
Hungary. Methods: Actual health insurance expenditure data for the base-case 
year (2013) were derived from the National Health Insurance Fund Administration 
(NHIFA) of Hungary and covered the following types of care: acute and chronic 
inpatient care, out-patient care, laboratory care, CT and MRI, drug, medical devices 
and home care. We analyzed health insurance expenditures according to age and 
gender. The prediction of future number of Hungarian population was calculated 
according to the population forecast of the Central Statistical Office of Hungary for 
2060. We applied 3 scenarios: basic, low and high number of population. Results: 
The actual health insurance expenditures of NHIFA was ö15.8 billion Hungarian 
Forint (HUF) in 2013 and the population of Hungary was 9910811 people. For the 
year 2030, health insurance expenditures were assessed 938.2 billion HUF while 
the population is predicted 9211522 people. For the year 2060, health insurance 
expenditures were assessed 908.5 billion HUF while the population is predicted 
7922289 people. Health insurance expenditures for population under 25 years was 
10.2 % of total expenditures, which decreased to 8.7 % in 2030 and 7.2 % in 2060. 
Health insurance expenditures for population over 65 years was 40.3 % of total 
expenditures, which increases to 47.0 % in 2030 and 58.9 % in 2060. ConClusions: 
Health insurance expenditures of Hungary will not increase significantly on actual 
level up to 2060. The reason behind this fact is the serious decline int he number of 
population. However, there will be a significant shift in the expenditures by decreas-
ing the proportion of population below 25 and increasing the proportion of people 
aged over 65 years.
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objeCtives: Italy has a tax-funded National Health System (NHS) that guar-
antees universal provision of comprehensive care. The central government 
provides policy and planning framework, defines the Essential Levels of Care 
and guarantees financial sustainability, while the regions are responsible 
for healthcare delivery and are liable for any budget deficit. Since 2005, cost-
containment and prescription appropriateness policies were developed in 
order to make regions more responsible on healthcare expenditure. The aim 
of this research was to provide an overview of national healthcare expendi-
ture trends before and after the implementation of such policies. Methods: 
Data published by the Minister for Economic and Financial Affairs were ana-
lysed to show different expenditure trends in different time periods: before 
2005 (period: 2002-2005) and after (2006-2013). Results: National healthcare 
expenditure from 2002-2013 increased by about € 30.28 billion (€ 78.97 in 2002 and 
€ 109.26 billion in 2013/year) with an average annual rate of +3.2%. Trends were 
different per period, with average annual rates of +5.4% in 2002-2005 and 
+1.3% in the period 2006-2013; +2.6% increase in the period 2006-2009 and 
-0.3% in 2010-2013. In the period 2006-2013, healthcare expenditures com-
ponents - such as healthcare professionals, general practitioners and hospi-
tal services - showed a lower average annual growth rate compared with the 
2002-2005 period. Territorial drug expenditures show a dramatic decrease 
compared to the previous period. ConClusions: Our analysis show that 
there is still room for better rationalise healthcare expenditure, however the 
greater empowerment of the regions and the policies implemented in recent 
years have improved the economic performance of the Italian healthcare 
expenditure.
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objeCtives: In Portugal, during the period 2002–2010, longevity (mean age at 
death) increased by 2.5 years. The aim of this study was to examine the effects of 
pharmaceutical innovation on the longevity from all diseases in Portugal (2002–
2010). Methods: Longitudinal disease-level data was analyzed to determine 
whether diseases for which there was greater pharmaceutical innovation - a larger 
nephrotic syndrome (1; 1.6%). ConClusions: Of the total of prescriptions, 76.1% 
were compliance with indications in national guidelines. However, unsubstantiated 
prescriptions represented a cost of around 22.0% of the total budget spent on the 
acquisition of albumin and that could have been applied in other unmet needs due 
to lack of financial resources.
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objeCtives: To assess the costs, benefits and savings of MobileCARE, an electronic 
health record (EHR) system smartphone application for clinical documentation 
developed by the United States Army and University of Miami, and implemented in a 
trauma intensive care unit (TICU). To evaluate provider perceptions of MobileCARE’s 
usability and impact on clinical workflow and productivity. Methods: A cost-
effectiveness and cost-utility analysis was conducted using hospital-level cost 
data and clinical outcomes data collected retrospectively at three time periods: 
pre-MobileCARE and two subsequent iterations of MobileCARE from 2010-2014. An 
analysis was performed of direct costs related to the mobile health intervention and 
benefits related to patient’s clinical outcomes. Qualitative interviews (n= 20) were 
conducted with providers working in the TICU and using MobileCARE. Ethnographic 
observation of clinical workflow and MobileCARE usage was conducted over the 
course of 12 days. Results: The total cost of MobileCARE was $2,655,639.67, con-
sisting of $1,943,399.47 towards platform development and a fixed, direct cost of 
implementation totaling $712,239.70. Transcription cost-savings per-provider were 
$79.25/month. Average length of stay decreased by 1.73 days, average mortality 
rate decreased by 2%, and QALDs increased by 1.8 QALD per patient over the study 
period. These clinical trends show directional improvement, although no significant 
differences were found. Overall, providers found MobileCARE acceptable, easy to 
use, positively impacted workflow, and increased their productivity. ConClusions: 
MobileCARE appears to be an affordable option for improving EHR usability, physi-
cian productivity, and clinical outcomes. The overall cost of developing MobileCARE 
is high, but consistent with similar technologies previously developed. The single-
time cost of implementation is justifiable given the ongoing cost-savings, time-
savings, indicated trends of clinical outcome benefits, and overall user acceptance 
of the system. MobileCARE is a viable option for TICU’s seeking low-cost and usable 
mobile documentation systems to enhance existing EHR system usability and effec-
tively reduce hospital transcription costs.
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objeCtives: An increase in prevalence of antimicrobial resistance among gram-
negative pathogens in complicated intra-abdominal infections (cIAI) has been noted 
recently (Sartelli et al 2013). A challenge in empiric treatment of cIAI is identifying 
initial appropriate antibiotic therapy (IAAT), which is associated with reduced length 
of stay and mortality compared with inappropriate therapy. Using local antibiogram 
data to select empiric therapy may increase the likelihood of IAAT. The objective of 
this research is to demonstrate how an economic model can assist medical decision-
making by identifying threshold differences in antibiotic resistance at which cef-
tolozane/tazobactam+metronidazole is cost-effective/cost-saving compared with 
piperacillin/tazobactam as IAAT. Methods: We used a decision analytic Monte 
Carlo simulation model (Kauf et al 2015) to compare cost and QALYs of persons 
infected with nosocomial gram-negative cIAI and treated empirically with either 
ceftolozane/tazobactam+metronidazole or piperacillin/tazobactam. We ran the 
model for baseline prevalence of resistance in the Program to Assess Ceftolozane/
Tazobactam Susceptibility (PACTS) in-vitro surveillance database. We limited thresh-
old analysis to three commonly isolated gram-negative pathogens: Escherichia coli, 
Klebsiella pneumoniae, and Pseudomonas aeruginosa. We assumed resistance for 
both drugs to be similar and then increased resistance in the piperacillin/tazobactam 
arm for all three pathogens simultaneously. Threshold differences in resistance at 
which ceftolozane/tazobactam became cost-effective were estimated. Results: 
At baseline resistance levels from PACTS, ceftolozane/tazobactam+metronidazole 
was cost-saving compared with piperacillin/tazobactam. Ceftolozane/tazobactam 
was cost-effective (cost-saving) when resistance rates for the three bacteria in the 
piperacillin/tazobactam were > 2% (7%) relative to ceftolozane/tazobactam. When 
resistance rates for E. coli alone were changed, ceftolozane/tazobactam was cost-
effective (cost-saving) at differences > 3% (13%). Results were sensitive to gram-
positive/-negative pathogen prevalence, drug/hospitalization cost. ConClusions: 
Economic models can be used to identify IAAT based on in-vitro resistance data. 
Once threshold differences in antibiotic resistance that make a comparator drug 
cost-effective are established, local antibiograms can help identify optimal IAAT.
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objeCtives: Ministry of Health, Labour and Welfare of Japan revises medical fee 
schedule biennially. The revision is performed in line with the government’s budget 
policy at national level. This study explored the influence of the manipulation of the 
medical fee schedule on National Hospital Organization (NHO) hospitals to overview 
